ReviewiScience2026
Decoding the role of cancer-associated fibroblasts in cisplatin resistance of head and neck squamous cell carcinoma.
Review in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cisplatin remains the primary chemotherapy drug for the treatment of head and neck squamous cell carcinoma (HNSCC). However, acquired resistance significantly limits its clinical application, contributing to treatment failure and a poor patient prognosis. Cancer-associated fibroblasts (CAFs) in the tumor microenvironment influence HNSCC sensitivity to cisplatin by modulating tumor cell responsiveness to treatment via paracrine signaling. CAFs impede deep penetration into tumors by remodeling the extracellular matrix (ECM). Various subtypes of cisplatin-resistant CAFs have been identified in HNSCC. Potential compounds targeting these subtypes could enhance cisplatin sensitivity. Simulation of the dynamic tumor microenvironment remains limited in research, hindering clinical translation. Bioinformatics has shifted research into cisplatin resistance in HNSCC. Single-cell sequencing and spatiotemporal transcriptomics could analyze the molecular profiles of CAFs that promote drug resistance in greater depth, potentially facilitating the development of highly targeted drugs and effective combination therapy strategies to overcome cisplatin resistance in HNSCCs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.